Two-part Phase 1b trial will evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of inhaled pan-JAK inhibitor KN-002 Study is being conducted at the Medicines Evaluation Unit in Manchester, UK [ … ]